Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on developmental toxicity

Description of key information

Supporting study: Test substance tested in pregnant S-D rats had teratogenic effects at doses 100, 50 and 25 mg/kg bw. At all mentioned doses was observed cleft palate and resorption, althought the 100% cleft palate and resorption was observed at dose 100 mg/kg bw. The adverse effects were not seen in the mothers nor in the fetuses at the doses of 10 and 5 mg/day.

Supporting study: In another study on developmental toxicity,test substance caused death of hamster females at doses 150 and 200 mg/kg/bw and at the dose of 100 mg/kg/bw was observed minor teratogenic effect.

Link to relevant study records

Referenceopen allclose all

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
supporting study
Reliability:
3 (not reliable)
Rationale for reliability incl. deficiencies:
significant methodological deficiencies
Remarks:
No GLP
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Deviations:
yes
Remarks:
Number of animals in tested group according the TG 414 should be 20 females. In present study, the number of animals was less than 12 in each group.
GLP compliance:
no
Limit test:
no
Species:
rat
Strain:
Sprague-Dawley
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Weight at study initiation: Female S-D rats 230-260g
- Diet (e.g. ad libitum): diets containing 50% ground sweet pea seeds (Lathyrus odoratus) obtained locally and from Argentina and ground Purina Laboratory Chow at various times at gestation.
Route of administration:
oral: gavage
Vehicle:
water
Details on exposure:
PREPARATION OF DOSING SOLUTIONS:Test substance was administrated to rats in aqueous solutions by oral intubation.
Analytical verification of doses or concentrations:
not specified
Details on mating procedure:
- Impregnation procedure: Females were mated with fertile males overnight.
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of gestation.
Duration of treatment / exposure:
During the days of gestation
Frequency of treatment:
Daily
Duration of test:
During the gestation, after that, the females were killed.
Dose / conc.:
100 mg/kg bw/day
Remarks:
Group 1
Dose / conc.:
50 mg/kg bw/day
Remarks:
Group 2
Dose / conc.:
25 mg/kg bw/day
Remarks:
Group 3
Dose / conc.:
10 mg/kg bw/day
Remarks:
Group 4
Dose / conc.:
5 mg/kg bw/day
Remarks:
Group 5
No. of animals per sex per dose:
5 groups.
Group number 1: 9 animals (100 mg/kg bw/day)
Group number 2: 8 animals (50 mg/kg bw/day)
Group number 3: 3 animals (25 mg/kg bw/day)
Group number 4: 11 animals (10 mg/kg bw/day)
Group number 5: 4 animals (5 mg/kg bw/day)
Control animals:
not specified
Details on study design:
The administration tested substance in aqueous solution was performed during the days of gestation.
Group number 1, 4 and 5: 12-15 days
Group number 2 and 3: 10-16 days
Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes:mortality

DETAILED CLINICAL OBSERVATIONS: Yes, mortality

Ovaries and uterine content:
Uterine content was examined after termination: Yes
Fetal examinations:
- External examinations: Yes:cleft palate and resorption
Fetuses were removed from the uterus 1 day before estimated term, examined for gross congenital malformations, and fixed in Bouin’s solution.
Clinical signs:
not examined
Dermal irritation (if dermal study):
not examined
Mortality:
mortality observed, treatment-related
Description (incidence):
Three of six pregnant rats treated daily with test substance in doses 100 mg during the days of gestations 12-15 died.
Body weight and weight changes:
not examined
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
no effects observed
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Other effects:
not examined
Number of abortions:
not examined
Pre- and post-implantation loss:
not examined
Total litter losses by resorption:
not examined
Early or late resorptions:
not examined
Dead fetuses:
not specified
Changes in pregnancy duration:
not examined
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined
Changes in number of pregnant:
not examined
Other effects:
not examined
Key result
Dose descriptor:
LOAEL
Effect level:
ca. 100 other: mg/day
Based on:
test mat.
Basis for effect level:
mortality
Fetal body weight changes:
not examined
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not examined
Reduction in number of live offspring:
effects observed, treatment-related
Description (incidence and severity):
Yes:
Doses: 100 mg/day 56% of resorption
50 mg/day- 38% of resorption
25 mg/day - 3 % of resorption
10 mg/day - 0 % of resorption
5 mg/day - 3% of resorption
Changes in sex ratio:
not examined
Changes in litter size and weights:
not examined
Changes in postnatal survival:
not examined
External malformations:
effects observed, treatment-related
Description (incidence and severity):
At the dose of 100 mg of tested substance, litters produced by surviving females had resorptions and 100% cleft palate.
At the doses of 25 and 50 mg cleft palate and resorptions were observed also.
Skeletal malformations:
not examined
Visceral malformations:
not examined
Other effects:
not examined
Key result
Dose descriptor:
NOAEL
Effect level:
ca. 10 other: mg/day
Based on:
test mat.
Sex:
not specified
Key result
Dose descriptor:
LOAEL
Effect level:
ca. 25 other: mg/day
Based on:
test mat.
Sex:
not specified
Key result
Abnormalities:
effects observed, treatment-related
Localisation:
external: face
Description (incidence and severity):
100 % Cleft palate - 100 mg/kg
Key result
Abnormalities:
effects observed, treatment-related
Localisation:
external: face
Description (incidence and severity):
95% Cleft palate - 50 mg/kg
Key result
Abnormalities:
effects observed, treatment-related
Localisation:
external: face
Description (incidence and severity):
43% Cleft palate - 25 mg/kg
Key result
Developmental effects observed:
yes
Lowest effective dose / conc.:
25 other: mg/day
Treatment related:
yes
Relation to maternal toxicity:
developmental effects in the absence of maternal toxicity effects
Dose response relationship:
yes
Relevant for humans:
no

Cleft palate and resorption produced by semicarbazide hydrochloride

No. Of females treated

Dose

mg/day

Days of gestation administrated

Resorptions

 

Cleft palate

No.                          %

No.                          %

6

100

12-15

28/50

56

22/22

100

8

50

10-16

26/68

38

40/42

95

3

25

10-16

1/29

3

12/28

43

11

10

12-15

0/107

0

0/107

0

4

5

12-15

1/33

3

0/32

0

3 animals from the first group (dose 100mg/day) died.

Conclusions:
Test substance tested in pregnant S-D rats had teratogenic effects at doses 100, 50 and 25 mg/kg bw. At mentioned doses was observed cleft palate and resorption, althought the 100% cleft palate and resorption was observed at dose 100 mg/kg bw. The adverse effects were not seen in the mothers nor in the fetuses at the doses of 10 and 5 mg/day.
Executive summary:

Test substance was tested on pregnant S-D rats for teratogenic effects. Rats were fed with sweet peas. Female rats (230-260g) were mated with fertile males overnight and checked by vaginal smears for insemination the followong morning. Animals were divided into 5 groups, each one contained different amount of animals which were administrated by test substance in aqueous solution by oral intubatiion during the day of gestation. Test substance was administrated at doses 100,50,25,10 and 5 mg/day. Three animals from the first group administrated at dose 100 mg/day died, but the surviving animals produced litters with resorptions of 56% and 100% cleft palate. Cleft palate and resorptions were also observed at doses 25 and 50 mg/day. At the dose 50 mg/day was observed 38% of resorption and 95% of cleft palate and in dose 25 mg/day 3% of resorption and 43 % of cleft palate. The adverse effects were not seen at the doses of 10 and 5 mg/day.

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
supporting study
Reliability:
3 (not reliable)
Rationale for reliability incl. deficiencies:
significant methodological deficiencies
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Deviations:
no
GLP compliance:
no
Limit test:
no
Species:
hamster, Syrian
Strain:
not specified
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: High Oak Ranch Ltd, Goodwood, Ont.
- Housing:After mating, gravid animals were kept in single wire cages
- Diet (e.g. ad libitum): Ad libitum,Purina lab Chow
- Water (e.g. ad libitum):ad libitum


ENVIRONMENTAL CONDITIONS
- Photoperiod (hrs dark / hrs light):12h/12h

Route of administration:
oral: gavage
Vehicle:
water
Remarks:
distilled
Details on exposure:
PREPARATION OF DOSING SOLUTIONS: All injections were given in aqueous solution on day 7 of gestation.
Analytical verification of doses or concentrations:
not specified
Details on mating procedure:
The animals were mated from 10.00-12.00 p.m and the following day designed as day 0 of gestation.
Duration of treatment / exposure:
One day (only on day 7 of gestation)
Frequency of treatment:
Once
Duration of test:
7 days, on day 14 animals were killed
Dose / conc.:
0 mg/kg bw/day
Remarks:
Untreated
Dose / conc.:
0 mg/kg bw/day
Remarks:
Vehicle treated controls
Dose / conc.:
100 mg/kg bw/day
Dose / conc.:
150 mg/kg bw/day
Dose / conc.:
200 mg/kg bw/day
No. of animals per sex per dose:
Not specified
Control animals:
yes, concurrent no treatment
yes, concurrent vehicle
Details on study design:
3 groups: 1. untreated, 2. vehicle treated controls receiving single dose of destilled water and 3. lathyrogen-treated animals.
Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes, observation of death.

Ovaries and uterine content:
The uterine content was examined after termination: Yes
Fetal examinations:
- External examinations: Yes: all per litter
Clinical signs:
not specified
Dermal irritation (if dermal study):
not examined
Mortality:
mortality observed, treatment-related
Description (incidence):
At the doses of 150 and 200 mg/kg bw maternal death was observed.
The females generally died within 48 h of administration of test substance.
Body weight and weight changes:
not examined
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
effects observed, treatment-related
Description (incidence and severity):
The autopsy revealed gravid uteri with all implantation sites showing signs of resorption.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Other effects:
not examined
Number of abortions:
not examined
Pre- and post-implantation loss:
not examined
Total litter losses by resorption:
not examined
Early or late resorptions:
not examined
Dead fetuses:
not examined
Changes in pregnancy duration:
not examined
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined
Changes in number of pregnant:
not examined
Other effects:
not examined
Key result
Dose descriptor:
LOAEL
Effect level:
ca. 150 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
mortality
Key result
Dose descriptor:
NOAEL
Effect level:
ca. 100 mg/kg bw/day
Based on:
test mat.
Fetal body weight changes:
not specified
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed
Field "Description (incidence and severity)" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.DescriptionIncidenceAndSeverityFetalPupBodyWeightChanges): Mean fetal weight of live fetuses (79) was not significantly reduced. Mean fetal weight (g) = 2.02+-0.68 (indicates the fetuses weighting less than 60% if the mean weight of the untretaed control fetuses, expressed as percent of live fetuses.
Reduction in number of live offspring:
effects observed, treatment-related
Description (incidence and severity):
At 100 mg/kg bw, 1% of fetal mortality was observed.
Changes in sex ratio:
not examined
Changes in litter size and weights:
not examined
Changes in postnatal survival:
not examined
External malformations:
effects observed, treatment-related
Description (incidence and severity):
The 5.1% of fetuses had malposition of the fore-and hindlimbs.
Skeletal malformations:
no effects observed
Description (incidence and severity):
No skeletal abnormalities at at dose of 100 mg/kg.
Visceral malformations:
no effects observed
Description (incidence and severity):
No visceral abnormalities at dose of 100mg/kg.
Other effects:
effects observed, treatment-related
Description (incidence and severity):
GROWTH RETARDATION: The 16.5% of lived fetuses showed growth retardation.
Key result
Dose descriptor:
LOAEL
Effect level:
ca. 100 mg/kg bw/day
Based on:
test mat.
Sex:
not specified
Key result
Abnormalities:
effects observed, treatment-related
Localisation:
skeletal: forelimb
skeletal: hindlimb
Description (incidence and severity):
Malformations at dose of 100 mg/kg bw
Key result
Developmental effects observed:
yes
Lowest effective dose / conc.:
100 mg/kg bw/day
Treatment related:
yes
Relation to maternal toxicity:
developmental effects in the absence of maternal toxicity effects
Dose response relationship:
yes
Relevant for humans:
no

No gross external, skeletal or visceral abnormalities were found among the litters of control groups (untreated and vehicle treated). Among the lathyrogen-treated litters, the most striking abnormalities were those of the anterior aspect of the central nervous system.

Conclusions:
Test substance caused death of hamster females at doses 150 and 200 mg/kg/bw and at the dose of 100 mg/kg/bw was observed minor teratogenic effect.
Executive summary:

Test substance was tested on hamster for teratogenic effects. Animals were divided into three groups and administrated by test substance in aqueous solution orally by gavage on day 7 of gestation at doses 100, 150 and 200 mg/kg/bw. The animals were killed on gestation day 14 and the contents of the uterus was examined. The two higher doses caused death of all the mothers, usually within 48h of dosing and all implants showed signs of resorptions. At 100 mg/kg bw, 1.3% of implants were dead or resorbed. Of the live fetuses, mean fetal weight was not significantly reduced. The 16.5% of fetuses showed growth retardation. No skeletal of visceral abnormalities were observed, however 5.1% of fetuses had malposition of the fore-and hindlimbs. According the results observed during this study, test substance appears to be mildly teratogenic in gestation and causes death of hamster females at doses 150 and 200 mg/kg/bw.

Effect on developmental toxicity: via oral route
Endpoint conclusion:
adverse effect observed
Quality of whole database:
K3,the documentation is not sufficient for assessment.
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available
Additional information

Supporting study:

Test substance was tested on pregnant S-D rats for teratogenic effects. Rats were fed with sweet peas. Female rats (230 -260g) were mated with fertile males overnight and checked by vaginal smears for insemination the followong morning. Animals were divided into 5 groups, each one contained different amount of animals which were administrated by test substance in aqueous solution by oral intubatiion during the day of gestation. Test substance was administrated at doses 100,50,25,10 and 5 mg/day. Three animals from the first group administrated at dose 100 mg/day died, but the surviving animals produced litters with resorptions of 56% and 100% cleft palate. Cleft palate and resorptions were also observed at doses 25 and 50 mg/day. At the dose 50 mg/day was observed 38% of resorption and 95% of cleft palate and in dose 25 mg/day 3% of resorption and 43 % of cleft palate. The adverse effects were not seen at the doses of 10 and 5 mg/day.

Supporting study:

Test substance was tested on hamster for teratogenic effects. Animals were divided into three groups and administrated by test substance in aqueous solution orally by gavage on day 7 of gestation at doses 100, 150 and 200 mg/kg/bw. The animals were killed on gestation day 14 and the contents of the uterus was examined. The two higher doses caused death of all the mothers, usually within 48h of dosing and all implants showed signs of resorptions. At 100 mg/kg bw, 1.3% of implants were dead or resorbed. Of the live fetuses, mean fetal weight was not significantly reduced. The 16.5% of fetuses showed growth retardation. No skeletal of visceral abnormalities were observed, however 5.1% of fetuses had malposition of the fore-and hindlimbs. According the results observed during this study, test substance appears to be mildly teratogenic in gestation and causes death of hamster females at doses 150 and 200 mg/kg/bw.

Justification for classification or non-classification

Some effects has been observed but the data has no good quality for assessment and, therefore, test substance can not be classified for developmental toxicity according to CLP Regulation (EC) no. 1272/2008.

Additional information